Nuclear Medicine and Biology
Volume 35, Issue 5 , Pages 599-604 , July 2008

In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia

  • Mario De Decker

      Affiliations

    • Department of Radiopharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
    • Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, Groningen, Netherlands
    • Corresponding Author InformationCorresponding author. Department of Radiopharmacy, University Ghent, 9000 Ghent, Belgium. Tel.: +32 09 332 30 28; fax: +32 09 332 38 07.
    • ,
  • Klaus Bacher

      Affiliations

    • Department of Medical Physics and Radiation Protection, Ghent University, Ghent, Belgium
    • ,
  • Hubert Thierens

      Affiliations

    • Department of Medical Physics and Radiation Protection, Ghent University, Ghent, Belgium
    • ,
  • Guido Slegers

      Affiliations

    • Department of Medical Imaging of Domestic Animals, Ghent University, Ghent, Belgium
    • ,
  • Rudi A. Dierckx

      Affiliations

    • Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, Groningen, Netherlands
    • ,
  • Filip De Vos

      Affiliations

    • Department of Radiopharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium

Received 5 October 2007 ,Revised 26 February 2008 ,Accepted 4 March 2008.

References 

  1. Chiorazzi N, Rai KR, Ferrarini M. Mechanisms of disease: chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804–815
  2. Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care. 2004;13(3):279–287
  3. Frampton JE, Wagstaff AJ. Alemtuzumab. Drugs. 2003;63(12):1229–1243
  4. Osterborg A, Dyer MJS, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol. 1997;15(4):1567–1574
  5. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10):3554–3561
  6. Knapp FF. Rhenium-188 — a generator-derived radioisotope for cancer therapy. Cancer Biother Radiopharm. 1998;13(5):337–349
  7. Griffiths GL, Goldenberg DM, Knapp FF, Callahan AP, Chang CH, Hansen HJ. Direct radiolabeling of monoclonal-antibodies with generator-produced Re-188 for radioimmunotherapy — labeling and animal biodistribution studies. Cancer Res. 1991;51(17):4594–4602
  8. Ferro-Flores G, Hashimoto K. Direct labeling of monoclonal antibodies and antibody fragments with Re-188 using a weak competing ligand. Radiochim Acta. 1997;79(1):63–70
  9. Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ, et al. Removal of T-cells from bone-marrow for transplantation — a monoclonal anti-lymphocyte antibody that fixes human-complement. Blood. 1983;62(4):873–882
  10. Dumont FJ. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond. Expert Rev Anticancer Ther. 2002;2(1):23–35
  11. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy. 2001;3(3):137–143
  12. Bläuenstein P, Locher JT, Seybold K, Koprivova H, Janoki GA, Macke HR, et al. Experience with the I-123 and Tc-99M labeled antigranulocyte antibody Mab47 — A comparison of labeling methods. Eur J Nucl Med. 1995;22(7):690–698
  13. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72(1):77–89
  14. Cloutier RJ, Smith SA, Watson EE, Snyder WS, Warner GG. Dose to fetus from radionuclides in bladder. Health Phys. 1973;25(2):147–161
  15. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100(3):768–773
  16. Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJS, Catovsky D, Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol. 1996;93(1):151–153
  17. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43(5):693–713
  18. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol. 2001;39(1--2):195–201
  19. Bunjes D, Buchmann I, Duncker C, Seitz U, Kotzerke J, Wiesneth M, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I–II study. Blood. 2001;98(3):565–572
  20. Buchmann I, Bunjes D, Kotzerke L, Martin H, Glatting G, Seitz U, et al. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities. Cancer Biother Radiopharm. 2002;17(2):151–163
  21. Zenz T, Buchmann I, Dohr D, Schlenk R, Grimminger W, von Harsdorf S, et al. Radio-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk chronic myeloid leukemia or Philadelphia chromosome positive ALL: results of a phase I–II study. Bone Marrow Transplant. 2003;31:S30–S31
  22. Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunol Immunother. 2006;55(2):188–196
  23. Knapp FF, Beets AL, Guhlke S, Zamora PO, Bender H, Palmedo H, et al. Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment. Anticancer Res. 1997;17(3B):1783–1795
  24. John E, Thakur ML, Defulvio J, Mcdevitt MR, Damjanov I. Rhenium-186-labeled Monoclonal-antibodies for radioimmunotherapy — preparation and evaluation. J Nucl Med. 1993;34(2):260–267
  25. Dadachova E, Mirzadeh S. The role of tin in the direct labelling of proteins with rhenium-188. Nucl Med Biol. 1997;24(6):605–608
  26. Seitz U, Neumaier B, Glatting G, Kotzerke J, Bunjes D, Reske SN. Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia. Eur J Nucl Med. 1999;26(10):1265–1273
  27. Iznaga-Escobar N. Direct radiolabeling of monoclonal antibodies with rhenium-188 for radioimmunotherapy of solid tumors — a review of radiolabeling characteristics, quality control and in vitro stability studies. Appl Radiat Isot. 2001;54(3):399–406

PII: S0969-8051(08)00073-5

doi: 10.1016/j.nucmedbio.2008.03.001

Nuclear Medicine and Biology
Volume 35, Issue 5 , Pages 599-604 , July 2008

Article Tools

* Image Usage & Resolution